Designating these cases as DHL/THL and qualifying with TdT expression (e.g., “High grade B-cell lymphoma with MYC and BCL2 rearrangements, and expression of TdT”) is preferred by the panel [46]. The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.